Tau NextGen is the first and so far only ongoing clinical trial of a combination therapy for the condition. Participants are being divided into two groups according to whether they already have symptoms of dementia or are expected to develop symptoms in the next 10 years. All participants will be given laconomab and a tau reducing antibody, but in different orders. Those without symptoms will receive the anti-tau antibody E2814 for a year, then have laconomab added. The symptomatic group will receive laconomab for six months and then have E2814 added. First results of the trial are expected after 2027. A similar US-based trial is being planned for sporadic late onset